You are here

Press Releases

Press Release | April 2, 2020

WASHINGTON, D.C. – President and CEO of AdvaMed Scott Whitaker released the following statement:

“Given recent allegations of price gouging in some parts of the country, it is important to be perfectly clear:

“Our member companies’ No. 1 priority is saving lives and at no time in our history has that been more apparent than over the past month as they have dramatically ramped up production of the diagnostics and devices that are essential to identifying, treating and combatting COVID-19.

Press Release | April 1, 2020

WASHINGTON, D.C. – The Advanced Medical Technology Association announced today that its member respiratory device companies have dramatically expanded the limits of their present production capacity in responding to the coronavirus outbreak, producing on average 2,000-3,000 ventilators per week, collectively, according to a recent survey of the seven member companies. In the coming weeks, company officials expect to ramp production to unprecedented levels, producing between an aggregated 5,000 and 7,000 ventilators per week in meeting the greatest needs across the nation. In 2019, when tallied together, these same companies were manufacturing approximately 700 ventilators per week for domestic distribution.

Press Release | March 31, 2020

WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today released the following statements by Scott Whitaker, AdvaMed president and CEO, and Susan Van Meter, executive director of AdvaMedDx, regarding the medtech industry’s ongoing response to the coronavirus pandemic:

Press Release | March 27, 2020

WASHINGTON, D.C. – Today, AdvaMed President and CEO Scott Whitaker released a statement applauding congressional passage of the Coronavirus Aid, Relief, and Economic Security (CARES) Act.

Press Release | March 24, 2020

WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today sent a letter to the Federal Emergency Management Agency (FEMA) and the administration calling for centralization of procurement and allocation decision-making for medical ventilators to address the coronanvius pandemic and help ensure appropriate access to health care providers and patients.

Press Release | March 20, 2020

WASHINGTON, D.C. – Several diagnostics companies have received or will soon receive FDA Emergency Use Authorizations (EUA) that will provide crucial capacity for the U.S. to significantly ramp up testing for the coronavirus (COVID-19). 

Press Release | March 17, 2020

WASHINGTON, D.C. – FDA Commissioner Dr. Stephen Hahn joined a special meeting of AdvaMed’s Board of Directors today to discuss how the medical technology industry and FDA can continue their work together to ensure patients and health care providers have the medical equipment they need to address the COVID-19 pandemic.    

Press Release | March 5, 2020

WASHINGTON, D.C. – AdvaMed President and CEO Scott Whitaker and AdvaMedDx Executive Director Susan Van Meter issued the following statements upon introduction today in the House and Senate of the Verifying Accurate, Leading-edge IVCT Development (VALID) Act for regulatory oversight of in vitro clinical tests (IVCTs) – including in vitro diagnostics (IVDs) and laboratory-developed tests (LDTs):

Press Release | February 26, 2020

WASHINGTON, D.C. – Since the onset of the coronavirus (COVID-19) outbreak, at least 31 AdvaMed member companies have donated medical products worth approximately $26.8 million and made cash donations worth $4.1 million to the China Red Cross Foundation and other medical institutions, such as hospitals and clinics in Hubei Province. Donations and the medtech community’s work will only grow in the coming weeks as the threat continues to elevate.

Press Release | February 19, 2020

WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) again urged the U.S. EPA to abandon its ethylene oxide (EtO) risk assessment value for one that is more feasible, based on the best available science and that will not potentially endanger the public health by threatening the availability of needed medical technologies.

Pages